Genomic Health Plans to Move Next-Gen Sequencing into Commercial Test Development within Two Years

Near term, Genomic Health expects next-gen sequencing to have an impact on biomarker identification, but over the next two to four years, the company plans to move the technology into its commercial development process.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.